tavapadon

Tavapadon is a highly selective, oral small molecule partial agonist of the dopamine D1 and D5 receptors. It is being developed as both monotherapy and adjunctive therapy for Parkinson's disease, with the aim of improving motor symptoms while minimizing side effects commonly associated with non-selective dopamine agonists that target D2/D3 receptors. Tavapadon's selectivity for D1/D5 receptors allows it to activate direct pathway medium spiny neurons in the nigrostriatal pathway, providing robust and sustained motor control. Its partial agonist activity reduces receptor overstimulation and desensitization, potentially leading to better tolerability and fewer adverse events compared to traditional dopaminergic therapies. The drug was originally discovered by Pfizer, further developed by Cerevel Therapeutics, and is now under AbbVie following acquisition[1][2][4][5][6].

Other names

tavapadonCVL-751CVL751CVL 751PF-06649751PF06649751PF 06649751PF-6649751PF6649751PF 6649751